Senescent cancer-associated fibroblasts in cancer progression: From formation to therapeutic opportunities
Mechanisms of Ageing and Development · 2026-04 · 230 · 112158
DOI: 10.1016/j.mad.2026.112158 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mechanisms of Ageing and Development, 2026-04. Verfasst von Yingying Feng und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for C…. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Neoplasms, Senescence-Associated Secretory Phenotype, Cellular Senescence. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 156 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer-associated fibroblasts (CAFs) are a key cellular component of the tumor microenvironment (TME), which comprises distinct subtypes, each exhibiting unique and significant roles in cancer development. Senescent cancer-associated fibroblasts (senCAFs) are a newly identified subset of CAFs characterized by high expression of senescence-associated markers. Notably, senCAFs significantly promote tumor malignancy through the secretion of diverse senescence-associated secretory phenotype (SASP) factors, such as interleukin-6 (IL-6), interleukin-8 (IL-8), matrix metalloproteinases (MMPs), and transforming growth factor-β (TGF-β), thereby facilitating tumor cell proliferation, invasion, angiogenesis, immunosuppression, and resistance to cancer therapy. Consequently, targeting senCAFs-either through selective clearance of this cell subset or suppression of their SASP-represents a promising approach for cancer treatment. Emerging therapies include pharmacological inhibition of key SASP regulatory pathways (e.g., JAK/STAT3 and NF-κB) and antagonists targeting individual SASP components. Additionally, senolytic agents and therapies targeting senCAF-specific markers (e.g., TSPAN8) are being actively explored. Furthermore, immunotherapies, including CAR-T cells targeting senescence-associated surface proteins, provide intriguing avenues. These advances highlight senCAFs as attractive therapeutic targets and underscore the potential for integrating SASP inhibitors and senolytic agents into precision oncology paradigms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking…
Förderung
- Chinese Academy of Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Feng, Y., Zhi, X., Xiao, T., & Feng, L. (2026). Senescent cancer-associated fibroblasts in cancer progression: From formation to therapeutic opportunities. Mechanisms of Ageing and Development, 230, 112158. https://doi.org/10.1016/j.mad.2026.112158
Vancouver
Feng Y, Zhi X, Xiao T, Feng L. Senescent cancer-associated fibroblasts in cancer progression: From formation to therapeutic opportunities. Mechanisms of Ageing and Development. 2026;230:112158. doi:10.1016/j.mad.2026.112158
BibTeX
@article{Feng2026,
author = {Feng, Yingying and Zhi, Xiaochen and Xiao, Ting and Feng, Lin},
title = {Senescent cancer-associated fibroblasts in cancer progression: From formation to therapeutic opportunities},
journal = {Mechanisms of Ageing and Development},
year = {2026},
volume = {230},
pages = {112158},
doi = {10.1016/j.mad.2026.112158}
}
EUVIMED